Valuation: Mymetics Corporation

Market Cap 439K 385K 356K 328K 618K 42.26M 626K 4.25M 1.66M 20.71M 1.65M 1.61M 71.5M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.22M 58.57M 53.91M 102M 6.95B 103M 699M 274M 3.4B 271M 265M 11.75B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
31.01
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-90.36% 45
+1.80%-0.83%+52.79%+86.50% 55.57B
-0.47%+0.85%+55.47%+58.07% 54.26B
+0.18%+2.13%-15.22%-14.97% 23.35B
+1.50%-1.35%+5.68%+415.28% 23.54B
+0.05%-1.77%+38.71%-4.22% 20.32B
-0.42%-2.61%+33.32%-31.46% 17.36B
+1.08%-3.63%+36.77%+547.87% 15.59B
0.00%-2.08%+165.40%+297.92% 14.96B
+1.06%+0.63%+26.80%+185.02% 14.11B
Average +5.03%-0.96%+106,696.64%+144.96% 23.91B
Weighted average by Cap. +0.60%-1.21%+43.98%+135.38%

Financials

2021 2022
Net sales 430K 377K 349K 321K 606K 41.41M 613K 4.17M 1.63M 20.3M 1.61M 1.58M 70.08M 1.03M 901K 835K 768K 1.45M 99M 1.47M 9.96M 3.9M 48.52M 3.86M 3.78M 168M
Net income -4.73M -4.15M -3.84M -3.54M -6.67M -456M -6.75M -45.85M -17.94M -223M -17.76M -17.37M -771M -4.8M -4.21M -3.9M -3.59M -6.77M -463M -6.85M -46.57M -18.23M -227M -18.04M -17.65M -783M
Net Debt 67.1M 58.81M 54.49M 50.16M 94.58M 6.46B 95.72M 650M 255M 3.17B 252M 246M 10.94B 71.68M 62.83M 58.22M 53.58M 101M 6.9B 102M 695M 272M 3.38B 269M 263M 11.68B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock